Banco Santander S.A. Has $2.72 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Banco Santander S.A. grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 9.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,711 shares of the company's stock after purchasing an additional 1,489 shares during the period. Banco Santander S.A.'s holdings in Zoetis were worth $2,723,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Zoetis by 0.5% in the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company's stock valued at $3,864,488,000 after purchasing an additional 95,856 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock valued at $2,030,813,000 after purchasing an additional 185,364 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Zoetis by 8.5% in the fourth quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company's stock valued at $906,202,000 after buying an additional 433,429 shares during the last quarter. Mizuho Securities USA LLC raised its holdings in shares of Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after buying an additional 4,829,815 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock valued at $761,221,000 after buying an additional 194,542 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Remove Ads

Zoetis Stock Up 1.8 %

NYSE:ZTS traded up $3.09 during trading hours on Friday, reaching $170.34. 3,296,788 shares of the stock were exchanged, compared to its average volume of 3,274,650. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The firm has a 50 day moving average of $166.72 and a 200 day moving average of $176.74. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock has a market cap of $76.28 billion, a PE ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. On average, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ZTS shares. Leerink Partnrs raised Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price target for the company. Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Finally, Piper Sandler boosted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $215.90.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.16% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.